Know What's Happening in Industry

Combination GLP-1 Therapy Reduces Fat Mass While Preserving Lean Muscle in Adults with Obesity

A recent double‑blind trial found that a combination of two GLP‑1 receptor agonists cut fat mass significantly while sparing lean muscle in adults with obesity. Over 24 weeks, participants lost an average of 5 % body fat, with lean mass decline limited to less than 1 %. The study involved 300 participants and reported safety comparable to monotherapy, with mainly mild gastrointestinal side effects. These findings point to a synergistic benefit of dual GLP‑1 therapy for weight management.